Daily non-political popular news in brief.

The impact of immunosuppressive medications on cardiovascular events in RA patients

Researchers at Harvard Medical School's Brigham and Women's Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients.

Read more »

Keywords: impact, immunosuppressive, medications, cardiovascular, events, patients, medication, event, patient

« Previous | Next »

Similar news on "The impact of immunosuppressive medications on cardiovascular events in RA patients":

1. Anti-anginal drug safe but not effective in reducing major cardiac events in ACS patients
   04-24-2007 · EurekAlert!
   The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
   Similar news · Read more »
   
2. Medication does not appear to improve symptoms or outcomes for patients with acute heart failure
   11-06-2007 · EurekAlert!
   The medication tezosentan, which was thought could be beneficial for the treatment of acute heart failure, did not improve breathlessness or reduce the risk of fatal or nonfatal cardiovascular events, according to a study in the Nov. 7 issue of JAMA.
   Similar news · Read more »
   
3. Clinical trials for diabetes drugs should measure outcomes important to patients
   09-27-2007 · EurekAlert!
   Most clinical trials for new diabetes drugs do not consider the impact medication will have on a patient's quality of life or other outcomes that are important to patients, such as the risk of developing complications associated with diabetes, according to a Mayo Clinic commentary in the current issue of the Lancet.
   Similar news · Read more »
   
4. Atherothrombosis associated with high rates of cardiovascular events within 1 year
   03-20-2007 · EurekAlert!
   Patients with arterial disease have relatively high rates of experiencing a cardiovascular event (such as heart attack, stroke or cardiovascular death) within one year, and these increase with the number of arterial locations afflicted, according to a large, international study in the March 21 issue of JAMA.
   Similar news · Read more »
   
5. Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events
   09-11-2007 · EurekAlert!
   A meta-analysis of previous research suggests that use of pioglitazone -- a glycemic control medication for patients with type 2 diabetes -- significantly reduces the risk of heart attack, stroke and death, but increases the risk for serious heart failure, according to an article in the Sept. 12 issue of JAMA.
   Similar news · Read more »
   
6. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
   12-20-2007 · EurekAlert!
   The largest study to examine the effect of depression on HIV treatment appears in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The study by Kaiser Permanente and Group Health found depression significantly worsens a patient's adherence to highly active antiretroviral therapy and clinical measures but that effective antidepressant medication reverses this outcome. The study looked at 3,359 HIV-infected patients to measure the effects of depression -- with and without SSRIs.
   Similar news · Read more »
   
7. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
   11-05-2007 · EurekAlert!
   Mayo Clinic researchers helped clarify a growing concern about the link between diabetes mellitus treatments and heart attack with the first large, population-based study showing that a group of common medications does not reduce diabetic patients' heart attack survival rates.
   Similar news · Read more »
   
8. Oral osteoporosis meds appear to reduce the risk of jaw degradation
   01-02-2008 · EurekAlert!
   Contrary to recent reports, oral osteoporosis medications that inhibit bone breakdown reduce the risk of jaw problems, based on an analysis of medical claims. Some doctors and dentists had advised patients who take oral osteoporosis medications such as Fosamax and Boniva to postpone dental work, fearing that tooth extractions and other procedures would exacerbate jaw problems purportedly linked to the medication. But the new findings refute the link and suggest the benefits of dentistry likely outweigh the risks for many of these patients.
   Similar news · Read more »
   
9. Patients at risk of adverse events within 3 months after stopping certain ACS therapy
   02-05-2008 · EurekAlert!
   Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the Feb. 6 issue of JAMA.
   Similar news · Read more »
   
10. Older medication may be more cost-effective for some patients with schizophrenia
    12-01-2006 · EurekAlert!
    A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia.
    Similar news · Read more »